Premium
Expression of epidermal growth factor receptor in urinary bladder cancer metastases
Author(s) -
Bue Peter,
Wester Kenneth,
Sjöström Anna,
Holmberg Anders,
Nilsson Sten,
Carlsson Jörgen,
Westlin JanErik,
Busch Christer,
Malmström PerUno
Publication year - 1998
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19980413)76:2<189::aid-ijc4>3.0.co;2-t
Subject(s) - urothelium , epidermal growth factor receptor , immunohistochemistry , urinary bladder , medicine , pathology , bladder cancer , monoclonal antibody , epidermal growth factor , cancer , cancer research , receptor , antibody , immunology
Bladder cancers frequently exhibit an increased number of epidermal growth factor receptors (EGFR) in comparison to normal urothelium. The EGFR could potentially be a target for toxic conjugates. The aim of our study was to compare the expression of EGFR in metastases with concurrent or primary tumour in the urinary bladder using immunohistochemical techniques and a monoclonal antibody. Tumour material from 20 patients was investigated. The majority (13/20) of the metastases were homogeneously stained and showed a moderate to strong membranous staining for EGFR. The expression of EGFR in primary bladder tumours and metastases was similar. There was no indication that tumour tissue exposed to chemotherapy or radiation had a decreased number of EGFR. Targeting of the EGFR thus seems potentially applicable to metastatic disease. Int. J. Cancer 76:189–193, 1998.© 1998 Wiley‐Liss, Inc.